Finally, elucidation of the mechanisms underlying the synthetic lethality between RAD52 and BRCA1/224–26 could identify potentially attractive therapeutic approaches for cancers in which BRCA1/2 is mutated. The gene discussed is RAD52; the disease is cancer.